Yu-Kun Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yu-Kun Li has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Chang-Ye Chen
Department of Gynecology, The First Affiliated Hospital of University of South China, Hengyang, 421001 People's Republic of China
1 shared publication Cheng-Yun Dou
The First Affiliated Hospital of University of South China
1 shared publicationChuang-Jie Cao
The First Affiliated Hospital of University of South China
1 shared publication- Gui-Fang Luo
Department of Gynecology, The First Affiliated Hospital of University of South China, Hengyang, Hunan 410011, PR China
1 shared publication - Guo Huang
Department of Thyroid and Breast Surgery, Shenzhen Second People’s Hospital, the First Affiliated Hospital of Shenzhen University, Shenzhen, China
1 shared publication Hai-Bo Tang
The First Affiliated Hospital of University of South China
1 shared publication
Latest Publications
- 31 October 2022
- Published by Springer Nature in Clinical and Translational Oncology
- Vol. 25 (3) , 578-591
Roles of oncogenes in esophageal squamous cell carcinoma and their therapeutic potentials
- 31 October 2022
- Published by Springer Nature in Clinical and Translational Oncology
- Vol. 25 (3) , 578-591
Roles of oncogenes in esophageal squamous cell carcinoma and their therapeutic potentials
- Open Access
- 8 October 2020
- Published by Springer Nature in Research Square
Identification of Prognostic Genes Associated with Expression Differentiation During Metabolism Process in Hepatocellular Carcinoma (HCC)
Background: Metabolic disorders have attracted more and more attention from scientists in the research of various tumors, especially in hepatocellular carcinoma (HCC). The purpose of this study is to assess the prognostic significance of metabolism in HCC.Methods: The expression profile of metabolism-related gene (MRGs) were extracted from the cancer genome atlas (TCGA) database of 349 HCC-surviving patients. Subsequently, A series of biomedical computational algorithms were used to identify seven-MRGs signature as a prognostic model. GSEA analysis indicated the function and pathway enrichment of these MRGs. Then, drug sensitivity analysis found the hub gene, which tested by IHC staining.Results: 420 differential MRGs and 116 differential transcription factor (TFs) expression were extracted from HCC patients based on TCGA database. Metabolic disturbance might be involved in the development of HCC by GO and KEGG enrichment analyses. LASSO regression analysis constructed seven-MRGs signature (DHDH, ENO1, G6PD, LPCAT1, PDE6D, PIGU and PPAT), which were used to predict the prognosis of HCC patients. Further GSEA analysis found the function and pathway enrichment of these seven MRGs. Then, drug sensitivity analysis indicated G6PD might play a key role in the prognosis of HCC by chemoresistance. Finally, we used IHC staining to demonstrate the relationship of G6PD expression and clinical parameter in HCC patients.Conclusion: This study provides a potential clue for predicting the prognosis of HCC patients and further studies on HCC metabolism.
- 8 October 2020
- Published by Springer Nature in Research Square
Open AccessIdentification of Prognostic Genes Associated with Expression Differentiation During Metabolism Process in Hepatocellular Carcinoma (HCC)
Background: Metabolic disorders have attracted more and more attention from scientists in the research of various tumors, especially in hepatocellular carcinoma (HCC). The purpose of this study is to assess the prognostic significance of metabolism in HCC.Methods: The expression profile of metabolism-related gene (MRGs) were extracted from the cancer genome atlas (TCGA) database of 349 HCC-surviving patients. Subsequently, A series of biomedical computational algorithms were used to identify seven-MRGs signature as a prognostic model. GSEA analysis indicated the function and pathway enrichment of these MRGs. Then, drug sensitivity analysis found the hub gene, which tested by IHC staining.Results: 420 differential MRGs and 116 differential transcription factor (TFs) expression were extracted from HCC patients based on TCGA database. Metabolic disturbance might be involved in the development of HCC by GO and KEGG enrichment analyses. LASSO regression analysis constructed seven-MRGs signature (DHDH, ENO1, G6PD, LPCAT1, PDE6D, PIGU and PPAT), which were used to predict the prognosis of HCC patients. Further GSEA analysis found the function and pathway enrichment of these seven MRGs. Then, drug sensitivity analysis indicated G6PD might play a key role in the prognosis of HCC by chemoresistance. Finally, we used IHC staining to demonstrate the relationship of G6PD expression and clinical parameter in HCC patients.Conclusion: This study provides a potential clue for predicting the prognosis of HCC patients and further studies on HCC metabolism.
- Open Access
- 28 February 2019
- Published by Springer Nature in Cancer Cell International
- Vol. 19 (1) , 44
FOXD3 may be a new cellular target biomarker as a hypermethylation gene in human ovarian cancer
FOXD3 is aberrantly regulated in several tumors, but its underlying mechanisms in ovarian cancer (OC) remains largely unknown. The present study aimed to explore the role and associated mechanisms of FOXD3 in OC. Microarray data from GEO was used to analyze differential CpG sites and differentially methylated regions (DMR) in tumor tissues and Illumina 450 genome-wide methylation data was employed. The FOXD3 expression level was determined through qRT-PCR and western blot analysis. Wound healing test, colony formation and flow cytometry assay were utilized to analyze cell migration, proliferation abilities, cell cycle and cell apoptosis, respectively. Finally, the effect of FOXD3 on tumor growth was investigated through in vivo xenograft experiments. GEO data analysis showed that FOXD3 was hypermethylated in OC tissues. Also, qRT-PCR revealed that FOXD3 was low expressed and methylation-specific PCR (MSP) confirmed that the methylation level of FOXD3 was hypermethylated. Combined treatment of 5-aza-2′-deoxycytidine (5-Aza-dC) could synergistically restored FOXD3 expression. Finally, in vitro and in vivo experiments showed that demethylated FOXD3 decreased cell proliferation and migration abilities, and increased the cell apoptosis. In vivo experiment detected that demethylated FOXD3 restrained tumor growth. FOXD3 could act as a tumor suppressor to inhibit cell proliferation, migration and promote cell apoptosis in OC cells.
- 28 February 2019
- Published by Springer Nature in Cancer Cell International
- Vol. 19 (1) , 44
Open AccessFOXD3 may be a new cellular target biomarker as a hypermethylation gene in human ovarian cancer
FOXD3 is aberrantly regulated in several tumors, but its underlying mechanisms in ovarian cancer (OC) remains largely unknown. The present study aimed to explore the role and associated mechanisms of FOXD3 in OC. Microarray data from GEO was used to analyze differential CpG sites and differentially methylated regions (DMR) in tumor tissues and Illumina 450 genome-wide methylation data was employed. The FOXD3 expression level was determined through qRT-PCR and western blot analysis. Wound healing test, colony formation and flow cytometry assay were utilized to analyze cell migration, proliferation abilities, cell cycle and cell apoptosis, respectively. Finally, the effect of FOXD3 on tumor growth was investigated through in vivo xenograft experiments. GEO data analysis showed that FOXD3 was hypermethylated in OC tissues. Also, qRT-PCR revealed that FOXD3 was low expressed and methylation-specific PCR (MSP) confirmed that the methylation level of FOXD3 was hypermethylated. Combined treatment of 5-aza-2′-deoxycytidine (5-Aza-dC) could synergistically restored FOXD3 expression. Finally, in vitro and in vivo experiments showed that demethylated FOXD3 decreased cell proliferation and migration abilities, and increased the cell apoptosis. In vivo experiment detected that demethylated FOXD3 restrained tumor growth. FOXD3 could act as a tumor suppressor to inhibit cell proliferation, migration and promote cell apoptosis in OC cells.